ReviewInternational journal of molecular sciences2022
Immunoglobulin G N-glycan Biomarkers for Autoimmune Diseases: Current State and a Glycoinformatics Perspective.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- Systems serology identifies FcR-related autoantibody signatures and functions for Sjögren's syndrome.EMBO molecular medicine · 2026Article
- Physical activity and IgG N-glycosylation in medical students: a cross-sectional study.Croatian medical journal · 2026Article
- Rhizospheric glycosyltransferase repertoires as a resource for enabling sustainable bioprocessing and green biocatalyst discovery.Scientific reports · 2026Article
- Integration of RNAseq transcriptomics andChemical science · 2025Article
- IgG glycosylation profiling of systemic lupus erythematosus using lectin microarray.Lupus science & medicine · 2025Article
- High-throughput glycosaminoglycan extraction and UHPLC-MS/MS quantification in human biofluids.Nature protocols · 2025Review
- GlyCompute: towards the automated analysis of protein N-linked glycosylation kinetics via an open-source computational framework.Analytical and bioanalytical chemistry · 2025Article
- Machine learning framework to extract the biomarker potential of plasma IgG N-glycans towards disease risk stratification.Computational and structural biotechnology journal · 2024Article
- Recent advances in N-glycan biomarker discovery among human diseases.Acta biochimica et biophysica Sinica · 2024Review
- The effects of immortalization on the N-glycome and proteome of CDK4-transformed lung cancer cells.Glycobiology · 2024Article
- Influence of plasma collection tubes on N-glycome in human blood samples.Practical laboratory medicine · 2024Article
- N-glycans from serum IgG and total serum glycoproteins specific for endometriosis.Scientific reports · 2023Article
- IgG N-glycan Signatures as Potential Diagnostic and Prognostic Biomarkers.Diagnostics (Basel, Switzerland) · 2023Review
- Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies.Frontiers in immunology · 2022Review
- mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine.Frontiers in immunology · 2022Article
- IgG subclass and Fc glycosylation shifts are linked to the transition from pre- to inflammatory autoimmune conditions.Frontiers in immunology · 2022Review
- The role of organ-deposited IgG in the pathogenesis of multi-organ and tissue damage in systemic lupus erythematosus.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effective treatment of autoimmune disorders can greatly benefit from disease-specific biomarkers that are functionally involved in immune system regulation and can be collected through minimally invasive procedures. In this regard, human serum IgG N-glycans are promising for uncovering disease predisposition and monitoring progression, and for the identification of specific molecular targets for advanced therapies. In particular, the IgG N-glycome in diseased tissues is considered to be disease-dependent; thus, specific glycan structures may be involved in the pathophysiology of autoimmune diseases. This study provides a critical overview of the literature on human IgG N-glycomics, with a focus on the identification of disease-specific glycan alterations. In order to expedite the establishment of clinically-relevant N-glycan biomarkers, the employment of advanced computational tools for the interpretation of clinical data and their relationship with the underlying molecular mechanisms may be critical. Glycoinformatics tools, including artificial intelligence and systems glycobiology approaches, are reviewed for their potential to provide insight into patient stratification and disease etiology. Challenges in the integration of such glycoinformatics approaches in N-glycan biomarker research are critically discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.